Ciprofloxacin Derivative-Loaded Nanoparticles Synergize with Paclitaxel Against Type II Human Endometrial Cancer

Youssef W Naguib; Suhaila O Alhaj-Suliman; Emad I Wafa; Sanjib Saha; Kareem Ebeid; Hamada H H Mohammed; Somaya A Abdel-Rahman; Gamal El-Din A Abuo-Rahma; Sean M Geary; Aliasger K Salem

doi:10.1002/smll.202302931

Back

Ciprofloxacin Derivative-Loaded Nanoparticles Synergize with Paclitaxel Against Type II Human Endometrial Cancer

Journal article

Open access

Peer reviewed

Ciprofloxacin Derivative-Loaded Nanoparticles Synergize with Paclitaxel Against Type II Human Endometrial Cancer

Youssef W Naguib, Suhaila O Alhaj-Suliman, Emad I Wafa, Sanjib Saha, Kareem Ebeid, Hamada H H Mohammed, Somaya A Abdel-Rahman, Gamal El-Din A Abuo-Rahma, Sean M Geary and Aliasger K Salem

Small (Weinheim an der Bergstrasse, Germany), Vol.20(41), e2302931

10/10/2024

DOI: 10.1002/smll.202302931

PMCID: PMC10828114

PMID: 37525558

Appears in UI Libraries Support Open Access

Files and links (1)

url

https://doi.org/10.1002/smll.202302931View

Published (Version of record) Open Access

Abstract

Combinations of chemotherapeutic agents comprise a clinically feasible approach to combat cancers that possess resistance to treatment. Type II endometrial cancer is typically associated with poor outcomes and the emergence of chemoresistance. To overcome this challenge, a combination therapy is developed comprising a novel ciprofloxacin derivative-loaded PEGylated polymeric nanoparticles (CIP2b-NPs) and paclitaxel (PTX) against human type-II endometrial cancer (Hec50co with loss of function p53). Cytotoxicity studies reveal strong synergy between CIP2b and PTX against Hec50co, and this is associated with a significant reduction in the IC50 of PTX and increased G2/M arrest. Upon formulation of CIP2b into PEGylated polymeric nanoparticles, tumor accumulation of CIP2b is significantly improved compared to its soluble counterpart; thus, enhancing the overall antitumor activity of CIP2b when co-administered with PTX. In addition, the co-delivery of CIP2b-NPs with paclitaxel results in a significant reduction in tumor progression. Histological examination of vital organs and blood chemistry was normal, confirming the absence of any apparent off-target toxicity. Thus, in a mouse model of human endometrial cancer, the combination of CIP2b-NPs and PTX exhibits superior therapeutic activity in targeting human type-II endometrial cancer.

Endometrial Cancer

UIOWA OA Agreement

ciprofloxacin derivative

nanomedicine

paclitaxel

PEGylated polymeric nanoparticles

Details

Title: Subtitle: Ciprofloxacin Derivative-Loaded Nanoparticles Synergize with Paclitaxel Against Type II Human Endometrial Cancer
Creators: Youssef W Naguib
Suhaila O Alhaj-Suliman - University of Iowa
Emad I Wafa - University of Iowa, Pharmaceutical Sciences and Experimental Therapeutics
Sanjib Saha - University of Iowa
Kareem Ebeid - University of Iowa
Hamada H H Mohammed - Minia University
Somaya A Abdel-Rahman - University of Iowa
Gamal El-Din A Abuo-Rahma - Minia University
Sean M Geary - University of Iowa, Pharmaceutical Sciences and Experimental Therapeutics
Aliasger K Salem - University of Iowa, Pharmaceutical Sciences and Experimental Therapeutics
Resource Type: Journal article
Publication Details: Small (Weinheim an der Bergstrasse, Germany), Vol.20(41), e2302931
DOI: 10.1002/smll.202302931
PMID: 37525558
PMCID: PMC10828114
NLM abbreviation: Small
ISSN: 1613-6810
eISSN: 1613-6829
Publisher: Wiley
Language: English
Electronic publication date: 07/31/2023
Date published: 10/10/2024
Academic Unit: Roy J. Carver Department of Biomedical Engineering; Pharmaceutical Sciences and Experimental Therapeutics; Craniofacial Anomalies Research Center; Dental Research; Chemical and Biochemical Engineering
Record Identifier: 9984449950102771

Metrics

15 Record Views

16 Times Cited - Web of Science